Immunotherapy has been integrated into the management of many primary cancers with great outcomes. This talk provides the latest advances in the use of immunotherapies for urologic and other primary malignancies.

Continuing Education Instructions and Disclosure Information:

Contact hours available until 4/3/24.

Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online nursing continuing professional development evaluation. You will be able to print your NCPD certificate at any time after you complete the evaluation.

Disclosure of relevant financial relationships with ineligible companies (planners, faculty/speakers, reviewers):

Planning Committee Disclosures:
Christina Hicks, MS, APRN, WHNP-BC discloses that she is a consultant for Urovant Sciences, Ltd.

There are no other Planning Committee disclosures to declare.

Speaker Disclosures:
There are no speaker disclosures to declare.

Commercial Support:
No commercial support declared.

Accreditation Statement:
The Society of Urologic Nurses and Associates (SUNA) is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

SUNA accreditation is reciprocal in the states and specialty organizations that recognize the ANCC-COA accreditation process. SUNA is an approved provider of continuing nursing education by the California Board of Registered Nursing, Provider Number CEP 5556. Accreditation and approved provider status of NCPD does not imply ANCC-COA approval or endorsement of any product, advertising, or educational content. SUNA urges all participants to be aware of the requirements for re-licensure in the states in which they hold a license.

Learning Outcome:
After completing this education activity, the learner will be able to discuss the latest advances in the use of immunotherapies for urologic and other primary malignancies.